Modality
ERT
MOA
PI3Ki
Target
MDM2
Pathway
Checkpoint
Cervical CaMDD
Development Pipeline
Preclinical
~Jan 2023
→ ~Apr 2024
Phase 1
Jul 2024
→ Jul 2030
Phase 1Current
NCT04980972
2,488 pts·Cervical Ca
2024-07→2030-07·Terminated
2,488 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-174.3y awayPh2 Data· Cervical Ca
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1/2
Termina…
Catalysts
Ph2 Data
2030-07-17 · 4.3y away
Cervical Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04980972 | Phase 1/2 | Cervical Ca | Terminated | 2488 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |